Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05530889
Other study ID # CR-6494
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date January 15, 2024
Est. completion date May 13, 2024

Study information

Verified date January 2024
Source Johnson & Johnson Vision Care, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This will be a prospective, randomized, bilateral eye, crossover, non-masked single site pilot study to compare the severity of symptoms of itching between test and control lens after two weeks of wear.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 13, 2024
Est. primary completion date May 13, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Potential participants must satisfy all of the following criteria to be enrolled in the study 1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Be at least 18 years of age at the time of screening. 4. By self-report, habitually wear soft, daily, spherical contact lenses in both eyes. Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 5 days per week during the last 4 weeks. 5. Willing to wear study lenses for at least 5 days per week and 6 hours per day. 6. Possess a wearable pair of spectacles that provide correction for distance vision and agree to wear them on the day of the dispense visit (V2). 7. Must agree and be willing to not wear their habitual contact lenses on the day of the lens dispense visit (V2) 8. Report symptoms of allergy, including itchy eyes. 9. Oral medication and/or eye drops to treat allergy symptoms must have been used for at least 2 weeks, for a minimum of 3 times per week, prior to the screening visit. 10. Must be willing to cease use of habitual eye drops to relieve allergy symptoms during the ACUVUE® Theravision® with Ketotifen wear period. 11. The spherical equivalent of the participant's vertex corrected distance refraction must be between -0.50 and -7.00 DS (inclusive) in each eye. 12. The magnitude of the cylindrical component of the participant's vertex-corrected distance refraction must be no more than -1.00 DC (inclusive) in each eye. 13. Must achieve best corrected visual acuity (BCVA) of at least +0.20 logMAR in each eye. Exclusion Criteria: Potential participants who meet any of the following criteria will be excluded from participating in the study: 1. Be currently using any ocular medications, with the exception of eye drops for the treatment of their allergy symptoms. 2. Take any medications for which a stable regimen has not been achieved (i.e. have started a new medication or changed dosage of an existing medication within the last four weeks). 3. Have a known hypersensitivity or allergic reaction to ketotifen or sodium fluorescein. 4. Have participated in a contact lens or lens care product clinical trial within 14 days prior to study enrollment. 5. Be an employee (e.g., Investigator, Coordinator, Technician) of the Centre for Ocular Research & Education listed on the study Delegation Log or immediate family member of these employees (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse). 6. Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.). 7. Be currently using bifocal, multifocal or monovision contact lenses, or wear lenses in an extended wear modality (sleep in lenses) 8. Have any active ocular infection of any type. 9. Have clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear. 10. Have clinically significant (grade 3 or 4) papillary conjunctivitis or bulbar injection which might interfere with contact lens wear and that are unlikely to be related to their ocular allergy (at the investigator's discretion). 11. Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
TEST Lens
ACUVUE® Theravision® with Ketotifen
CONTROL Lens
1-DAY ACUVUE® MOIST.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Johnson & Johnson Vision Care, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Subjective rating of itchiness The severity of symptoms of itching will be compared (0-4 itching scale with 0.5 steps) between the test and control lens after 2 weeks of wear. up to 2-week follow-up
Secondary Subjective rating of comfort Subjective ratings of comfort will be assessed on a 0 to 100 scale after each 2-week wear period. up to 2-week follow-up
Secondary Subjective rating of dryness Subjective ratings of dryness will be assessed on a 0 to 100 scale after each 2-week wear period. up to 2-week follow-up
Secondary Subjective rating of vision Subjective ratings of vision will be assessed on a 0 to 100 scale after each 2-week wear period. up to 2-week follow-up
Secondary Subjective rating of handling Subjective ratings of handling will be assessed on a 0 to 100 scale after each 2-week wear period. up to 2-week follow-up
Secondary CLDEQ-8 Questionnaire CLDEQ-8 is a dry eye questionnaire that asks the participant to reflect and rate their symptoms of eye discomfort and dryness over the past two weeks. A higher composite score indicates more severe dryness and the range is 0-37. up to 2-week follow-up
Secondary Comfortable and total CL wear time Total wearing time and total comfortable wearing time will be recorded after each 2-week wear period. up to 2-week follow-up
Secondary Subject Preference Questionnaire The subject will select their preferred study lens, test lens or control lens. at the 2-week follow-up
Secondary MiniRQLQ Questionnaire The MiniRQLQ is a validated questionnaire that focuses on the impact of allergies on quality of life (QoL). It includes 14 questionnaire items in five sections (activities, practical problems, nasal symptoms, ocular symptoms, general symptoms) that address how allergies impacted QoL during the previous week, by asking the user to rate how troubling each item in the questionnaire was perceived. up to 2-week follow-up
See also
  Status Clinical Trial Phase
Completed NCT00431392 - Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions Phase 2
Completed NCT06161012 - Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over Two Weeks of Wear N/A
Terminated NCT00708357 - Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head? Phase 0
Completed NCT05291936 - Clinical Evaluation of Two Daily Disposable Toric Soft Contact Lenses Over One Week of Wear N/A
Withdrawn NCT00712777 - Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism N/A
Completed NCT00709423 - Effects of Moxaverine and Placebo on Ocular Blood Flow Phase 2
Completed NCT00708929 - Does Complement Factor H Gene Polymorphism Play a Role in the Regulation of Vascular Tone in the Choroid? N/A
Completed NCT00712400 - Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects N/A
Completed NCT01663688 - Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye N/A
Completed NCT05427539 - Feasibility Evaluation of Daily Disposable Toric Soft Contact Lenses Manufactured With an Alternative Hydration Process N/A
Completed NCT05713552 - Evaluation of ACUVUE® OASYS 1-Day for Astigmatism Contact Lenses With Alternative Lidstock N/A
Withdrawn NCT00406731 - Role of Endothelin- and Nitric Oxide-system in the Regulation of Optic Nerve Head Blood Flow During Changes in Ocular Perfusion Pressure Phase 2
Completed NCT00706927 - Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension N/A
Completed NCT00275730 - Effects of Indomethacin on Retinal and Choroidal Blood Flow in Healthy Volunteers N/A
Completed NCT00712764 - Role of Adenosine in the Control of Choroidal Blood Flow During Changes in Ocular Perfusion Pressure. N/A
Completed NCT00312416 - Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise Phase 4
Completed NCT00712907 - Effects of Vitamin C on Hyperoxia-Induced Reduction of Retinal Blood Flow N/A
Completed NCT00431730 - Is There a Difference in Flicker Induced Vasodilatation Between Smokers and Non-Smokers? N/A
Withdrawn NCT00991900 - Short Term and Day to Day Reproducibility of Reflectometric Measurement of Retinal Oxygen Saturation in Healthy Subjects
Completed NCT00280462 - Choroidal Blood Flow Regulation During Isometric Exercise: Effects of Ca2+-Channel Blockade N/A